Bristol-Myers, Alembic Settle Patent Suit on Top Seller Revlimid

Bristol-Myers Squibb Co.’s Celgene Corp. and Alembic Pharmaceuticals Ltd. settled a patent-infringement lawsuit over Alembic’s proposed generic version of Revlimid, the blockbuster blood-cancer therapy and Celgene’s top seller, according to a filing in New Jersey federal court.

Alembic is blocked from making copies until the patent has expired “and is further enjoined from assisting or cooperating with any third parties in connection with any infringement” of the patent as to “any lenalidomide-containing drug product that references” Revlimid—“unless and to the extent otherwise specifically authorized by Celgene,” according to a proposed consent judgment filed July 1 in the US District Court ...